Artia Global Partners LP trimmed its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 49.7% during the fourth quarter, HoldingsChannel reports. The fund owned 17,400 shares of the biopharmaceutical company’s stock after selling 17,170 shares during the quarter. Alnylam Pharmaceuticals comprises 1.0% of Artia Global Partners LP’s holdings, making the stock its 18th largest position. Artia Global Partners LP’s holdings in Alnylam Pharmaceuticals were worth $6,919,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Align Financial LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $7,906,000. Guggenheim Capital LLC lifted its position in shares of Alnylam Pharmaceuticals by 365.3% in the 4th quarter. Guggenheim Capital LLC now owns 40,135 shares of the biopharmaceutical company’s stock worth $15,960,000 after purchasing an additional 31,510 shares during the period. Caisse de depot et placement du Quebec lifted its position in shares of Alnylam Pharmaceuticals by 189.5% in the 4th quarter. Caisse de depot et placement du Quebec now owns 51,598 shares of the biopharmaceutical company’s stock worth $20,518,000 after purchasing an additional 33,772 shares during the period. Schonfeld Strategic Advisors LLC lifted its position in shares of Alnylam Pharmaceuticals by 362.4% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 44,894 shares of the biopharmaceutical company’s stock worth $17,852,000 after purchasing an additional 35,185 shares during the period. Finally, AQR Capital Management LLC lifted its position in shares of Alnylam Pharmaceuticals by 23.6% in the 4th quarter. AQR Capital Management LLC now owns 919,959 shares of the biopharmaceutical company’s stock worth $365,822,000 after purchasing an additional 175,951 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.
Alnylam Pharmaceuticals Stock Up 0.3%
Alnylam Pharmaceuticals stock opened at $282.72 on Thursday. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94. Alnylam Pharmaceuticals, Inc. has a 12-month low of $276.94 and a 12-month high of $495.55. The firm’s fifty day moving average is $302.00 and its 200 day moving average is $339.75. The company has a market capitalization of $37.75 billion, a PE ratio of 77.25 and a beta of 0.29.
Insider Buying and Selling
In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the transaction, the director owned 1,582 shares in the company, valued at approximately $473,302.76. This represents a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Melissa Mclaughlin sold 2,286 shares of the company’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $330.42, for a total transaction of $755,340.12. Following the transaction, the insider owned 9,443 shares in the company, valued at approximately $3,120,156.06. The trade was a 19.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 7,740 shares of company stock valued at $2,420,214 in the last three months. Insiders own 0.86% of the company’s stock.
Wall Street Analyst Weigh In
A number of research analysts have recently issued reports on the stock. Truist Financial dropped their price target on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating on the stock in a research report on Monday, April 13th. Jefferies Financial Group restated a “hold” rating and issued a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a research report on Monday, March 16th. Chardan Capital restated a “buy” rating and issued a $425.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 25th. Citigroup assumed coverage on shares of Alnylam Pharmaceuticals in a research report on Tuesday, May 19th. They issued a “buy” rating and a $380.00 price target on the stock. Finally, Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $463.13.
Get Our Latest Stock Report on ALNY
Alnylam Pharmaceuticals Profile
Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.
Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.
Read More
- Five stocks we like better than Alnylam Pharmaceuticals
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
